Monoclonal antibodies against viruses and bacteria: A survey of patents

Recent Patents on Anti-Infective Drug Discovery

Volumn 2, Issue 3, 2007, Pages 171-177

  Xiao, Xiaodong ^a   Dimitrov, Dimiter S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Antibodies; Bacteria; Patents; Therapeutics; Viruses

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2F5; MONOCLONAL ANTIBODY 4E10; MONOCLONAL ANTIBODY 8AH7AL; MONOCLONAL ANTIBODY 8AH8AL; MONOCLONAL ANTIBODY C40; MONOCLONAL ANTIBODY E16; MONOCLONAL ANTIBODY E24; MONOCLONAL ANTIBODY E34; NEUTRALIZING ANTIBODY; PALIVIZUMAB; POLYCLONAL ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ANTIMICROBIAL THERAPY; BACILLUS ANTHRACIS; BACTERIAL INFECTION; CLINICAL TRIAL; CLOSTRIDIUM BOTULINUM; COMBINATION CHEMOTHERAPY; COMMERCIAL PHENOMENA; DRUG APPROVAL; DRUG EFFICACY; DRUG MARKETING; FOOD AND DRUG ADMINISTRATION; HENDRA VIRUS; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPROMISED PATIENT; IMMUNOTHERAPY; INFLUENZA; MONOTHERAPY; NEWBORN DISEASE; NIPAH VIRUS; NONHUMAN; PATENT; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; SEVERE ACUTE RESPIRATORY SYNDROME; UNITED STATES; VACCINIA VIRUS; VIRUS INFECTION; WEST NILE FLAVIVIRUS; YERSINIA PESTIS; YERSINIOSIS;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-HIV AGENTS; ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; BACTERIAL TOXINS; HEPACIVIRUS; HEPATITIS C; HIV-1; HUMANS; PATENTS AS TOPIC; VIRUS DISEASES;

EID: 36749025848     PISSN: 1574891X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489107782497272     Document Type: Review

References (99)

1. Casadevall A. Passive antibody therapies: progress and continuing challenges. Clin Immunol 1999; 93(1): 5-15.
2. Casadevall A, Scharff MD. Return to the past: the case for antibody-based therapies in infectious diseases. Clin Infect Dis 1995; 21(1): 150-61.
3. Casadevall A, Scharff MD. Serum therapy revisited: animal models of infection and development of passive antibody therapy. Antimicrob Agents Chemother 1994; 38(8): 1695-702.
4. Zeitlin L, Cone RA, Moench TR, Whaley KJ. Preventing infectious disease with passive immunization. Microbes Infect 2000; 2(6): 701-708.
5. Sawyer LA. Antibodies for the prevention and treatment of viral diseases. Antiviral Res 2000; 47(2): 57-77.
6. Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV. Intravenous immunoglobulin for infectious diseases: back to the pre-antibiotic and passive prophylaxis era? Trends Pharmacol Sci 2004; 25(6): 306-10.
7. DesJardin JA, Snydman DR. Antiviral immunotherapy - a review of current status. Biodrugs 1998; 9: 487-507.
8. Moudgil A, Shidban H, Nast CC, et al. Parvovirus B19 infection-related complications in renal transplant recipients: treatment with intravenous immunoglobulin. Transplantation 1997; 64(12): 1847-50.
9. Kurtzman G, Frickhofen N, Kimball J, Jenkins DW, Nienhuis AW, Young NS. Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its core with immunoglobulin therapy. N Engl J Med 1989; 321(8): 519-23.
10. Kerr JR, Cunniffe VS, Kelleher P, Bernstein RM, Bruce IN. Successful intravenous inummoglobulin therapy in 3 cases of parvovirus B19-associated chronic fatigue syndrome. Clin Infect Dis 2003; 36(9): 100-106.
11. Koduri PR, Kumapley R, Valladares J, Teter C. Chronic pure red cell aplasia caused by parvovirus B19 in AIDS: use of intravenous immunoglobulin-a report of eight patients. Am J Hematol 1999; 61(1): 16-20.
12. Clayton AJ. Lassa immune serum. Bull World Health Organ 1977; 55(4): 435-9.
13. Krasnianskii VP, Gradoboev VN, Borisevich IV, et al. Development and study of properties of inummoglobulins against Lassa fever. Vopr Virusol 1997; 42(4): 168-71.
14. Shimoni Z, Niven MJ, Pitlick S, Bulvik S. Treatment of West Nile virus encephalitis with intravenous immunoglobulin. Emerg Infect Dis 2001; 7(4): 759.
15. Hamdan A, Green P, Mendelson E, Kramer MR, Pitlik S, Weinberger M. Possible benefit of intravenous immunoglobulin therapy in a lung transplant recipient with West Nile virus encephalitis. Transpl Infect Dis 2002; 4(3): 160-2.
16. Pasic S, Jankovic B, Abinun M, Kanjuh B. Intravenous immunoglobulin prophylaxis in an echovirus 6 and echovirus 4 nursery outbreak. Pediatr Infect Dis J 1997; 16(7): 718-20.
17. Rotbart HA, O'Connell JF, McKinlay MA. Treatment of human enterovirus infections. Antiviral Res 1998; 38(1): 1-14.
18. Masci S, De Simone C, Famularo G, et al. Intravenous immunoglobulins suppress the recurrences of genital herpes simplex virus: a clinical and immunological study. Immunopharmacol Immunotoxicol 1995; 17(1): 33-47.
19. Vassilenko SM, Vassilev TL, Bozadjicv LG, Bineva IL, Kazarov GZ. Specific intravenous immunoglobulin for Crimean-Congo haemorrhagic fever. Lancet 1990; 335(8692): 791-92.
20. Enria DA, Briggiler AM, Fernandez NJ, Levis SC, Maiztegui JI. Importance of dose of neutralising antibodies in treatment of Argentine haemorrhagic fever with immune plasma. Lancet 1984; 2(8397): 255-56.
21. Ali MB. Treating severe acute respiratory syndrome with hyperimmune globulins. Hong Kong Med J 2003; 9(5): 391-92.
22. Burnouf T, Radosevich M. Treatment of severe acute respiratory syndrome with convalescent plasma. Hong Kong Med J 2003; 9(4): 309.
23. Vittecoq D, Chevret S, Morand-Joubert L, et al. Passive immunotherapy in AIDS: a double-blind randomized study based on transfusions of plasma rich in anti-human immunodeficiency virus 1 antibodies vs. transfusions of seronegative plasma. Proc Natl Acad Sci USA 1995; 92(4): 1195-99.
24. Jablonowski H, Sander O, Willers R, Adams O, Bartmann P, Wahn V. The use of intravenous immunoglobulins in symptomatic HIV infection. Results of a randomized study. Clin Investig 1994; 72(3): 220-24.
25. Olopoenia L, Young M, White D, Barnes S, Rahbar F, Fomufod A. Intravenous immunoglobulin in symptomatic and asymptomatic children with perinatal HIV infection. J Natl Med Assoc 1997; 89(8): 543-47.
26. Guay LA, Musoke P, Hom DL, et al. Phase I/II trial of HIV-1 hyperimmune globulin for the prevention of HIV-1 vertical transmission in Uganda. AIDS 2002; 16(10): 1391-400.
27. Dezube BJ, Proper J, Zhang J, et al. A passive immunotherapy, (PE)HRG214, in patients infected with human immunodeficiency virus: a phase I study. J Infect Dis 2003; 187(3): 500-503.
28. Zolla-Pazner S, Gorny MK. Passive immunization for the prevention and treatment of HIV infection. AIDS 1992; 6: 1235-47.
29. Wu H, Pfarr DS, Tang Y, et al. Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization. J Mol Biol 2005; 350(1): 126-44.
30. Choudhry V, Zhang MY, Dimitrova D, et al. Antibody-based inhibitors of HIV infection. Expert Opin Biol Ther 2006; 6(5): 523-31.
31. Zhou T, Xu L, Dey B, et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 2007; 445(7129): 732-37.
32. Moulard M, Phogat SK, Shu Y, et al. Broadly cross-reactive IIIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc Natl Acad Sci USA 2002; 99(10): 6913-18.
33. Labrijn AF, Poignard P, Raja A, et al. Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol 2003; 77(19): 10557-65.
34. Zhang MY, Dimitrov DS. Novel approaches for identification of broadly cross-reactive HIV-1 neutralizing human monoclonal antibodies and improvement of their potency. Curr Pharm Des 2007; 13(2): 203-12.
35. Choudhry V, Zhang MY, Sidorov IA, et al. Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies. Virology 2007; 363(1): 79-90.
36. Zhang MY, Choudhry V, Sidorov IA, et al. Selection of a novel gp41-specific HIV-1 neutralizing human antibody by competitive antigen panning. J Immunol Methods 2006; 317(1-2): 21-30.
37. Barth H, Liang TJ, Baumert TF. Hepatitis C virus entry: Molecular biology and clinical implications. Hepatology 2006; 44(3): 527-35.
38. Weiner AJ, Brauer MJ, Rosenblatt J, et al. Variable and bypervariable domains are found in the regions of Hcv corresponding to the flavivirus envelope and Ns1 proteins and the pestivirus envelope glycoproteins. Virology 1991; 180(2): 842-48.
39. Li W, Moore MJ, Vasibeva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003; 426(6965): 450-54.
40. Xiao X, Chakraborti S, Dimitrov AS, Gramatikoff & Dimitrov DS. The SARS-CoV S glycoprotein: expression and functional characterization. Biochem Biophys Res Commun 2003; 312(4): 1159-64.
41. a) Prabakaran P, Gan J, Feng Y, et al. Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody. J Biol Chem 2006; 281(23): 15829-36.
42. b) Zhu Z., Chakraborti S., and He Y., et al. Patent cross-reactive neutralization of SARS coronavirus isolated by human monoclonal antibodies. 2007; 104(29): 12123-12128.
43. Murray K, Selleck P, Hooper P, et al. A morbillivirus that caused fatal disease in horses and humans. Science 1995; 268(5207): 94-97.
44. Lee KE, Umapathi T, Tan CB, et al. The neurological manifestations of Nipah virus encephalitis, a novel paramyxovirus. Ann Neurol 1999; 46(3): 428-32.
45. Lim CC, Sitoh YY, Hui F, et al. Nipah viral encephalitis or Japanese encephalitis? MR findings in a new zoonotic disease. AJNR Am J Neuroradiol 2000; 21(3): 455-61.
46. Chua KB, Goh KJ, Wong KT, et al. Fatal encephalitis due to Nipah virus among pig-farmers in Malaysia. Lancet 1999; 354(9186): 1257-59.
47. Chow MH, Arguin PM, Shay DK, et al. Risk factors for Nipah virus infection among abattoir workers in Singapore. J Infect Dis 2000; 181(5): 1760-63.
48. Chua KB, Lam SK, Tan CT, et al. High mortality in Nipah encephalitis is associated with presence of virus in cerebrospinal fluid. Ann Neurol 2000; 48(5): 802-805.
49. Gob KJ, Tan CT, Chew NK, et al. Clinical features of Nipah virus encephalitis among pig farmers in Malaysia. N Engl J Med 2000; 342(17): 1229-35.
50. Update: outbreak of Nipah virus-Malaysia and Singapore, 1999. MMWR Morb Mortal Wkly Rep 1999; 48(16): 335-37.
51. Chua KB, Bellini WJ, Rota PA, et al. Nipah virus: a recently emergent deadly paramyxovirus. Science 2000; 288(5470): 1432-35.
52. Eaton BT. Introduction to Current focus on Hendra and Nipah viruses. Microbes Infect 2001; 3(4): 277-78.
53. Eaton BT, Broder CC, Middleton D, Wang LF. Hendra and Nipah viruses: different and dangerous. Nat Rev Microbiol 2006; 4(1): 23-35.
54. Mungall BA, Middleton D, Crameri G, et al. Feline model of acute nipah virus infection and protection with a soluble glycoprotein-based subunit vaccine. J Virol 2006; 80(24): 12293-302.
55. Murray K, Selleck P, Hooper P, et al. A morbillivirus that caused fatal disease in horses and humans. Science 1995; 268(5207): 94-97.
56. Anonymous. Emerging Infections update: November 2004 to January 2005. Communicable Disease Report Weekly (CDR Weekly) 2005; 15.
57. Halpin K, Hyatt AD, Plowright RK, et al. Emerging viruses: coming in on a wrinkled wing and a prayer. Clin Infect Dis 2007; 44(5): 711-17.
58. Enserink M. Emerging infections diseases. Nipah virus (or a cousin) strikes again. Science 2004; 303(5661): 1121.
59. Butler D. Fatal fruit bat virus sparks epidemics in southern Asia. Nature 2004; 429(6987): 7.
60. Hsu VP, Hossain MJ, Parashar UD, et al. Nipah virus encephalitis reemergence, Bangladesh. Emerg Infect Dis 2004; 10(12): 2082-87.
61. Nipah virus outbreak(s) in Bangladesh, January-April 2004. Wkly Epidemiol Rec 2004; 79(17): 168-71.
62. Anonymous. Person-to-person transmission of Nipah virus during outbreak in Faridpur District. Health Sci Bull (ICDDR,B) 2004; 2: 5-9.
63. Dimitrov DS. Virus entry: molecular mechanisms and biomedical applications. Nat Rev Microbiol 2004; 2(2): 109-22.
64. Wang LF, Yu M, Hansson E, et al. The exceptionally large genome of Hendra virus: support for creation of a new genus within the family Paramyxoviridac. J Virol 2000; 74(21): 9972-79.
65. Eaton BT, Mackenzie JS, Wang L-F. Henipaviruses. In: Knipe DM, Griffin DE, Lamb RA, Straus SE, Howley PM, Martin MA, et al., eds. Fields Virology. 5 ed. Philadelphia: Lippincott Williams & Wilkins 2007; p. 1587-600.
66. Zhu Z, Diraitrov AS, Bossart KN, et al. Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies. J Virol 2006; 80(2): 891-99.
67. Zhu Z, Dimitrov AS, Chakraborti S, et al. Development of human monoclonal antibodies against diseases caused by emerging and biodefense-related viruses. Expert Rev Anti Infect Ther 2006; 4(1): 57-66.
68. Henderson DA. Biological terrorism - The looming threat of bioterrorism. Science 1999; 283(5406): 1279-82.
69. Geoffrey L.Smith AVaML. The formation and function of extracellular enveloped vaccinia virus. J Gen Virol 2002; 83: 2915-31.
70. Moss B. Poxvirus entry and membrane fusion. Virology 2006; 344(1): 48-54.
71. De Clercq E. Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections. Clin Microbiol Rev 2001; 14(2): 382.
72. Chen ZC, Earl P, Americo J, et al. Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus. Proc Natl Acad Sci USA 2006; 103(6): 1882-87.
73. Brinton MA. The molecular biology of West Nile virus: A new invader of the Western hemisphere. Ann Rev Microbiol 2002; 56: 371-402.
74. Oliphant T, Engle M, Nybakken GE, et al. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med 2005; 11(5): 522-30.
75. Nybakken GE, Oliphant T, Johnson S, Burke S, Diamond MS, Fremont DH. Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature 2005; 437(7059): 764-68.
76. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289(2): 179-86.
77. Webster RG, Govorkova EA. Focus on research: H5N1 influenza - Continuing evolution and spread. New Engl J Med 2006; 355(21): 2174-77.
78. Palese P, Garcia-Sastre A. Influenza vaccines: present and future. J Clin Invest 2002; 110(1): 9-13.
79. Monto AS. The role of antivirals in the control of influenza. Vaccine 2003; 21(16): 1796-800.
80. Simmons CP, Bernasconi NL, Suguitan AL, et al. Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med 2007; 4(5): e178.
81. Baker M. Anti-infective antibodies: finding the path forward. Nat Biotechnol 2006; 24(12): 1491-93.
82. Perry RD, Fetherston JD. Yersinia pestis - Etiologic agent of plague. Clin Microbiol Rev 1997; 10(1): 35-66.
83. Andrews GP, Heath DG, Anderson GW, Welkos SL, Friedlander AM. Fraction 1 capsular antigen (F1) purification from Yersinia pestis CO92 and from an Escherichia coli recombinant strain and efficacy against lethal plague challenge. Infect Immum 1996; 64(6): 2180-87.
84. Du YD, Rosqvist R, Forsberg A. Role of fraction I antigen of Yersinia pestis in inhibition of phagocytosis. Infect Immun 2002; 70(3): 1453-60.
85. Heath DG, Anderson GW, Mauro JM, et al. Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine. Vaccine 1998; 16(11-12): 1131-37.
86. Titball RW, Howells AM, Oyston PCF, Williamson ED. Expression of the Yersinia pestis capsular antigen (F1 antigen) on the surface of an aroA mutant of Salmonella typhimurium induces high levels of protection against plague. Infect Immun 1997; 65(5): 1926-30.
87. Cornelis GR. The Yersinia deadly kiss. J Bacteriol 1998; 180(21): 5495-504.
88. Hueck CJ. Type III protein secretion systems in bacterial pathogens of animals and plants. Microbiol Mol Biol Rev 1998; 62(2): 379.
89. Rosqvist R, Forsberg A, Wolfwatz H. Intracellular targeting of the Yersinia Yope cytotoxin in mammalian-cells induces actin microfilament disruption. Infect Immun 1991; 59(12): 4562-69.
90. Rosqvist R, Magnusson KE, Wolfwatz H. Target-cell contact triggers expression and polarized transfer of yersinia yope cytotoxin into mammalian-cells. EMBO J 1994; 13(4): 964-72.
91. Schiavo G, van der Goot FG. The bacterial toxin toolkit. Nat Rev Mol Cell Biol 2001; 2(7): 530-37.
92. Arnon SS, Schechter R, Inglesby TV, et al. Botulinum toxin as a biological weapon - Medical and public health management. JAMA 2001; 285(8): 1059-70.
93. Mahant N, Clouston PD, Lorentz IT. The current use of botulinum toxin. J Clin Neurosci 2000; 7(5): 389-94.
94. Tournier JN, Quesnel-Hellmann A, Cleret A, Vidal DR. Contribution of toxins to the pathogenesis of inhalational anthrax. Cell Microbiol 2007; 9(3): 555-65.
95. Hepburn MJ, Purcell BK, Paragas J. Pathogenesis and sepsis caused by organisms potentially utilized as biologic weapons: Opportunities for targeted intervention. Curr Drug Targets 2007; 8(4): 519-32.
96. Bradley KA, Mogridge J, Mourez M, Collier RJ, Young JAT. Identification of the cellular receptor for anthrax toxin. Nature 2001 8; 414(6860): 225-29.
97. Mosier DE, Gulizia RJ, Baird SM, Wilson DB. Transfer of a functional human immune-system to mice with severe combined immunodeficiency. Nature 1988 15; 335(6187): 256-59.
98. Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. Monoclonal antibody successes in the clinic. Nat Biotechnol 2005; 23(9): 1073-78.
99. Beeler JA, Coelingh KV. Neutralization epitopes of the f-glycoprotein of respiratory syncytial virus - effect of mutation upon fusion function. J Virol 1989; 63(7): 2941-50.